8.16
前日終値:
$8.35
開ける:
$8.2
24時間の取引高:
957.07K
Relative Volume:
0.67
時価総額:
$543.46M
収益:
$2.81M
当期純損益:
$-97.34M
株価収益率:
-5.1646
EPS:
-1.58
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
-6.53%
1か月 パフォーマンス:
-14.55%
6か月 パフォーマンス:
+6.53%
1年 パフォーマンス:
+151.08%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics Inc
|
8.16 | 556.11M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - Bitget
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat
FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia
Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada
BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7 By Investing.com - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownWhat's Next? - MarketBeat
Fulcrum Therapeutics Shares Surge on Promising Clinical Trial Data and Strong Financial Runway - NewsCase
Positive Developments in Fulcrum Therapeutics (FULC) Boost Inves - GuruFocus
Fulcrum Therapeutics Q4 Earnings Call Highlights - MarketBeat
Fulcrum Therapeutics (FULC) Shares Experience Unexpected Decline - GuruFocus
Fulcrum Therapeutics (FULC) Surpasses Expectations with Phase Ib Study Results - GuruFocus
FULC: Pociredir at 20 mg achieved strong HbF induction and clinical benefit in severe sickle cell disease - TradingView
What's Going On With Fulcrum Therapeutics Stock Tuesday? - Benzinga
Fulcrum Therapeutics Says Phase 1b Pociredir Trial Demonstrates Improvement in Sickle Cell Disease Therapy - marketscreener.com
Earnings call transcript: Fulcrum Therapeutics Q4 2025 reports progress in sickle cell treatment - Investing.com
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Fulcrum Therapeutics (FULC) Reports Promising PIONEER Trial Resu - GuruFocus
Fulcrum Therapeutics stock tumbles despite trial results By Investing.com - Investing.com Canada
Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million. - Bitget
Fulcrum Therapeutics stock tumbles despite trial results - Investing.com Australia
FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings - Quiver Quantitative
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics announces positive results from 20 mg dose cohort of phase 1b pioneer trial of Pociredir - marketscreener.com
Fulcrum Therapeutics (NASDAQ: FULC) posts wider 2025 loss and boosts cash runway - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights - GlobeNewswire
Experimental sickle cell pill left most patients crisis-free for 12 weeks - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - Bitget
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Bitget
Aberdeen Group plc Acquires 79,265 Shares of Fulcrum Therapeutics, Inc. $FULC - Defense World
Will Fulcrum Therapeutics Inc. stock benefit from infrastructure spending2025 Pullback Review & Low Drawdown Momentum Trade Ideas - mfd.ru
Fulcrum Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Why Fulcrum Therapeutics Inc. stock attracts high net worth investorsEarnings Recap Report & Reliable Volume Spike Alerts - mfd.ru
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% HigherWhat's Next? - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside - DirectorsTalk Interviews
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Fulcrum Therapeutics Inc. stock a contrarian buyPortfolio Risk Report & Fast Gain Stock Tips - mfd.ru
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):